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Abstract. Mr= 109.13, orthorhombic, P212121, a= 
7.098 (1), b=7.225 (1), c= 10.980 (3)A, V= 
563.09A 3, Z -4 ,  D m=1.29, D x=l .29Mgm -a, 
2 (CuKs)=l .54178A,  p=0.70mm -~. Final R= 
0.059 for 425 significant reflections measured at 298 K. 
The pyrazole portion is planar, while the dihydro- 
imidazole group has a shallow half-chair confor- 
mation with C(4) deviating by 0.136 (4) A out of the 
plane of this ring. 
lntroduetlon. The title compound (NSC 51143: IMPY, 
I) is a potent and selective inhibitor of DNA synthesis 
(Ennis, M611er, Wang & Selawry, 1971), and is currently 
being evaluated for clinically useful anti-tumour activity 
(Vogel, Denefrio, Padgett & Silverman, 1980). Evidence 
has been obtained demonstrating that IMPY acts by 
inhibiting the ribonucleotide-reductase enzyme system 
(Cory & Fleischer, 1980), possibly by binding to a 
non-haem iron site. As a first step in the establishment 
of structure-activity relationships for IMPY and its 
0108-2701/83/030353-02501.50 
congeners, its molecular structure has been established. 
This is the first reported X-ray study of an imidazo- 
[ 1,2-b]pyrazole system. 
H H 
HI4 
(I) 
Experimental. Large prismatic crystals of IMPY ob- 
tained from aqueous solution, D m determined by 
flotation, crystal ca 0.60 x 0.40 x 0.15 mm sealed in 
glass capillary tube so as to avoid the excessive 
decomposition oted at an earlier stage, preliminary 
X-ray photographs howed orthorhombic symmetry, 
systematic absences h00: h = 2n + 1; 0k0: k = 2n + 1; 
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00h l=  2n + 1, accurate cell dimensions obtained by 
least-squares analysis of 25 0 values, Enraf-Nonius 
CAD-4 diffractometer, monochromated Cu Kct 
radiation, reflections within range 1.5 < 0 < 60.0 ° (h: 
0 to 7; k: 0 to 8; h 0 to 12) measured using e)--20 
scans, maximum count time 60s; intensities of three 
standard reflections (305, 211 and 41 i )  monitored at 
intervals of 3600s had decreased in intensity by 
~ 8% during course of data collection and corrections 
for crystal decay were applied to data set; 526 total 
reflections, 425 with I > 30(/) considered observed; 
structure solved by direct methods using MULTAN 80 
(Main et al., 1980) and refined on F by full-matrix least 
squares, H-atom positions located from difference 
Fourier syntheses and kept fixed during refinement, 
final difference map did not show any peaks > 
0-15e A -a, final R = 0.055, R w = 0.059, w = 1/o'(F) 2, 
zero shift/error in final least-squares cycle, F(000)= 
232, atomic scattering factors taken from International 
Tables for X-ray Crystallography (1974), all cal- 
culations performed on a PDP11/34A computer using 
SDP program system (Frenz, 1980). 
Discussion. The final atomic parameters are listed in 
Table 1.* The molecular structure of IMPY is shown in 
Fig. 1; bond distances and angles are given in Table 2. 
* Tables of structure factors, H-atom coordinates and anisotropic 
thermal parameters have been deposited with the British Library 
Lending Division as Supplementary Publication No. SUP 
38220 (5 pp.). Copies may be obtained through The Executive 
Secretary, International Union of Crystallography, 5 Abbey 
Square, Chester CH 1 2HU, England. 
Table 1. Final fractional coordinates (×10 4) and 
average thermalparameters (A 2 x 10 3) 
E.s.d.'s are in parentheses. 
x y z (Uii) 
N(1) 2098 (5) 4819 (6) 716 (3) 47 
N(2) 1483 (6) 3157 (6) 2384 (4) 50 
N(3) 3379 (6) 5817 (6) 66 (4) 54 
C(1) 4579 (7) 4969 (8) 1925 (4) 54 
C(2) 4850 (7) 5926 (7) 814 (5) 55 
C(3) 250 (7) 4072 (7) 459 (5) 58 
C(4) -299 (8) 3388 (8) 1718 (5) 59 
C(5) 2775 (6) 4265 (6) 1808 (4) 40 
Table 2. Bond lengths (A) and angles (°)for the non-H 
atoms 
E.s.d.'s are in parentheses. 
C(5)-C(I) 1.384 (4) N(3)--N(1) 1.363 (3) 
C(5)--N(I) 1.352 (3) N(1)--C(3) 1.446 (4) 
C(5)--N(2) 1.371 (4) N(2)--C(4) 1-471 (4) 
C(1)--C(2) 1.416 (4) C(4)--C(3) 1.519 (5) 
C(2)--N(3) 1.330 (4) 
C(1)-C(5)-N(1) 107.6 (3) C(5)-N(I)-N(3) 112.6 (2) 
C(1)-C(5)-N(2) 142.2 (3) C(5)--N(1)--C(3) 112.6 (3) 
N(1)-C(5)-N(2) 110.1 (2) N(3)-N(1)-C(3) 134.4 (3) 
C(5)-C(I)-C(2) 103.0 (3) C(5)--N(2)-C(4) 106.2 (2) 
C(1)--C(2)-N(3) 113.4 (3) N(2)-C(4)-C(3) 105.6 (3) 
C(2)--N(3)--N(I) 103.4 (2) N(1)--C(3)-C(4) 100.2 (3) 
Fig. 1. The molecular structure of IMPY, showing the numbering 
scheme used. 
Fig. 2. A view approximately parallel to the molecular best plane. 
The analysis has confirmed the structure assigned to 
the imidazo[ 1,2-b]pyrazole system, with neither N atom 
of the pyrazole group carrying a proton. It is 
noteworthy that bonds N(1)-C(5) and N(2)-C(5) 
have substantial double-bond character, presumably on 
account of their delocalization with the aromaticity of 
the pyrazole ring. This portion of the molecule is planar, 
whereas the dihydroimidazole group is significantly 
buckled (Fig. 2) into a shallow half-chair, with C(4) 
deviating by 0.136 (4) A from the plane of this ring. 
The Cancer Research Campaign is thanked for 
support. IMPY was a gift from the Drug Synthesis and 
Chemistry Branch, Division of Treatment, National 
Cancer Institute. 
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